CALM1

CALM1 encodes calmodulin, a Ca²⁺ sensor that governs Ca²⁺-dependent inactivation (CDI) of the cardiac L-type calcium channel CaV1.2, and pathogenic missense variants in this protein cause inherited ventricular arrhythmia syndromes (calmodulinopathies) (PMID:26969752, PMID:28158429). Disease variants act through distinct but converging defects: E141G reduces Ca²⁺-binding affinity ~11-fold and produces a dominant loss of CaV1.2 CDI with mild accentuation of NaV1.5 late current but no effect on RyR2-mediated Ca²⁺ release (PMID:26969752); F142L severely impairs CDI of ICaL, augmenting plateau-phase inward current and prolonging repolarization in a manner reversed by the ICaL blocker verapamil (PMID:28158429); and N98S confers β-adrenergically induced ICaL dysregulation that promotes delayed and early afterdepolarization-driven triggered activity (PMID:32929985). Because the three CALM genes are functionally interchangeable at the protein level, suppression of all three calmodulin transcripts combined with replacement of a shRNA-immune CALM1 cDNA shortens pathologically prolonged action potential duration across CALM1, CALM2, and CALM3 variant cardiomyocytes, establishing a pan-calmodulinopathy therapeutic strategy (PMID:39069900). Beyond the heart, CALM1 has a non-redundant role in neuronal migration: knockdown of Calm1 (but not its paralogs) disrupts both tangential and radial precerebellar neuron migration (PMID:25519244), and its long 3'-UTR isoform, generated by alternative polyadenylation in neural tissue, is required for dorsal root ganglion neuron migration and experience-induced hippocampal activation (PMID:32522888). Calmodulin protein output in axons is itself regulated post-transcriptionally, with FMRP and miR-181d repressing Calm1 mRNA in axonal granules until NGF triggers its release to support local translation and axon elongation (PMID:26711345). CALM1 transcription is controlled by its core promoter and 5' UTR, and CaM-dependent signaling supports expression of cartilage matrix genes Col2a1 and Agc1 in chondrocytes (PMID:15746150, PMID:9681195).

1. 1998 Medium

   Established that the three calmodulin-encoding genes are not transcriptionally equivalent, raising the question of gene-specific regulation despite identical protein products.

   Evidence Nuclear run-on, mRNA quantification, and 5' UTR luciferase reporter assays in human teratoma cells

   PMID:9681195

   Open questions at the time

   • Does not identify the trans-factors driving differential CALM gene transcription
   • Performed in a single proliferating cell type
2. 2005 Medium

   Connected CALM1 promoter activity and CaM signaling to a downstream biological output, placing calmodulin upstream of cartilage matrix gene expression.

   Evidence Promoter SNP luciferase reporter assays plus pharmacological CaM inhibition with Col2a1/Agc1 readout in chondrogenic cells

   PMID:15746150

   Open questions at the time

   • Pharmacological CaM inhibition is not CALM1-specific
   • Direct transcriptional targets of CaM signaling not defined
3. 2013 Low

   Linked CALM1 genetically to inherited ventricular fibrillation, implicating disruption of CaM–target peptide interaction as an arrhythmia mechanism.

   Evidence Exome sequencing and segregation analysis in a family with idiopathic VF; mechanistic inference from prior structural literature on residue F90

   PMID:24076290

   Open questions at the time

   • F90 mechanistic role cited from prior literature, not re-demonstrated experimentally here
   • No functional channel assay for the F90L variant
4. 2014 Medium

   Demonstrated a non-redundant neurodevelopmental role for Calm1 distinct from its paralogs, answering whether the three calmodulin genes are functionally interchangeable in vivo.

   Evidence RNAi knockdown of individual Calm genes in mouse hindbrain with histological analysis of precerebellar neuron migration

   PMID:25519244

   Open questions at the time

   • Molecular effectors downstream of Calm1 in migrating neurons unknown
   • Single lab, acute knockdown only
5. 2015 Medium

   Revealed post-transcriptional control of axonal calmodulin levels, showing how Calm1 mRNA is spatially restrained and de-repressed to regulate axon growth.

   Evidence Co-IP of FMRP with Calm1 mRNA/miR-181d, genetic perturbations, and local translation assays in primary sensory neurons with NGF stimulation

   PMID:26711345

   Open questions at the time

   • Single Co-IP system; direct miR-181d binding site on Calm1 not mapped functionally
   • Whether this pathway operates in non-sensory neurons unknown
6. 2016 High

   Defined the biophysical mechanism of a calmodulinopathy variant, showing reduced Ca²⁺ affinity translates to dominant loss of CaV1.2 inactivation rather than RyR2 dysfunction.

   Evidence Ca²⁺-binding affinity assay, patch-clamp of CaV1.2 and NaV1.5, and intracellular Ca²⁺ release assay in heterologous systems for E141G

   PMID:26969752

   Open questions at the time

   • Heterologous expression may not capture native cardiomyocyte channel context
   • Contribution of NaV1.5 late current to phenotype not quantified
7. 2017 High

   Confirmed CDI impairment as the primary arrhythmic mechanism in a patient-relevant model and showed it is pharmacologically reversible.

   Evidence Patch-clamp and Ca²⁺ measurements in patient-derived hiPSC-CMs with dynamic clamp and verapamil rescue for F142L

   PMID:28158429

   Open questions at the time

   • Verapamil rescue is mechanistic proof-of-concept, not a clinical therapy
   • Variant-specific differences across calmodulinopathy mutations not addressed
8. 2020 High

   Established an in vivo arrhythmia mechanism for the N98S variant, showing β-adrenergic stress unmasks ICaL dysregulation that drives triggered activity.

   Evidence CRISPR knock-in mouse, patch-clamp, optical voltage mapping, Ca²⁺ imaging, and His-Purkinje microelectrode recordings with β-adrenergic modulation

   PMID:32929985

   Open questions at the time

   • Mouse cardiac electrophysiology differs from human
   • Molecular basis of the β-adrenergic sensitivity not fully resolved
9. 2020 Medium

   Identified an isoform-specific neural function for the long 3'-UTR Calm1 mRNA, separating coding-independent regulatory roles from protein function.

   Evidence CRISPR deletion of the distal poly(A) site, smFISH localization, and in vivo DRG migration and hippocampal activation phenotyping in knock-in mice

   PMID:32522888

   Open questions at the time

   • Trans-factors binding the long 3'-UTR not identified
   • Mechanism linking isoform to phenotypes undefined
10. 2024 Medium

    Provided proof-of-principle that a single suppression-and-replacement construct can correct the action potential phenotype across all three calmodulin genes, exploiting their protein-level redundancy therapeutically.

    Evidence shRNA knockdown plus shRNA-immune CALM1 cDNA replacement with APD90 measurement in patient iPSC-CMs carrying CALM1/CALM2/CALM3 variants

    PMID:39069900

    Open questions at the time

    • In vitro iPSC-CM model only; no in vivo delivery demonstrated
    • Long-term safety and off-target effects not assessed
11. 2025 Low

    Implicated CALM1 in a cancer drug-resistance pathway via stabilization and CAMKK2-linked autophagy, extending calmodulin function beyond cardiac and neural contexts.

    Evidence Drug-target binding assay, Western blot for CALM1 stability and CAMKK2 phosphorylation, autophagy markers, and xenograft model in 5-FU-resistant colorectal cancer

    PMID:40976489

    Open questions at the time

    • Binding assay methodology unspecified (no SPR/ITC)
    • Direct CALM1–CAMKK2 interaction not mechanistically detailed
    • Single lab

• How calmodulin's identical protein product is differentially deployed across cardiac, neuronal, and chondrogenic contexts — and which target effectors mediate each role — remains unresolved.
• Tissue-specific CaM target effectors largely uncharacterized in this corpus
• Structural basis distinguishing variant-specific CDI defects not unified
• Regulatory factors governing CALM gene/isoform expression not identified